August 2011

Scleroderma Treatment With Autologous Transplant (STAT) Study

Condition:   Systemic Scleroderma
Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified January 2017

Reduced Intensity Double Umbilical Cord Blood Transplantation

Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Acute Myelogenous Leukemia
Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Radiation: Total Body Radiation;   Biological: Cord Blood
Sponsor:   Massachusetts General Hospital
Recruiting - verified April 2016